MedTrace Logo

Phase II Study of Celecoxib and Concurrent Radiotherapy in Stage II-III NSCLC

NCT00181532 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2009-06-30

No results posted yet for this study

Summary

The purpose of this study is to investigate the effect of the adminstration of celecoxib, a cox2-inhibitor in patients with stage II-III non small cell lung cancer receiving radical radiotherapy.

The hypothesis is that celecoxib will increase the remission rate of radiotherapy.

Conditions

  • Non Small Cell Lung Carcinoma

Interventions

DRUG

Celecoxib

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Maastricht Radiation Oncology

    lead OTHER

Principal Investigators

  • Dirk De Ruysscher, PHD · Maastricht Radiation Oncology (MAASTRO-clinic)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-05-31
Completion
2008-01-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00181532 on ClinicalTrials.gov